CD4+ and CD8+ T cell responses were analyzed using an activation-induced marker (AIM) assay (using CD137 and OX40 as markers for CD4+ T cell activation and CD137 and CD69 as markers for CD8+ T cell activation) after stimulation with a peptide pool against full-length WT spike or Omicron spike in 39/80 patients with blood cancer (Table 1). The gene discussed is CD8A; the disease is hematopoietic and lymphoid system neoplasm.